News Kura Oncology, Inc.

Equities

KURA

US50127T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
18.75 ^USD	+0.11%		+0.86%	+30.39%

Apr. 22	Sector Update: Health Care Stocks Advance Premarket Monday	MT
Apr. 22	Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 22	MT
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	Apr. 22	DJ
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	Apr. 22	MT
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	Apr. 22	AQ
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	Apr. 22	CI
Kura Oncology to Participate in Stifel Targeted Oncology Forum	Apr. 10	AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	AQ
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM	Mar. 14
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	Mar. 06	AQ
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	Mar. 06	CI
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Mar. 04	AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	AQ
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024	Feb. 27
Kura Oncology: Q4 Earnings Snapshot	Feb. 27	AQ
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 27	AQ
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	Feb. 26	AQ
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	Feb. 26	CI
Kura Oncology to Participate in Three Upcoming Investor Conferences	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kura Oncology, Inc.

Equities

KURA

US50127T1097

Summary

Filters